BRIEF-Cingulate Presents Positive Phase 3 Results for CTx-1301

Reuters10-28

Oct 28 (Reuters) - Cingulate Inc CING.O:

CINGULATE PRESENTS POSITIVE PHASE 3 RESULTS FOR CTX-1301 DEMONSTRATING STATISTICALLY SIGNIFICANT EFFICACY AND ENTIRE ACTIVE-DAY SYMPTOM CONTROL

Source text: ID:nGNX57NmLC

Further company coverage: CING.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2578951980?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-28 20:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2578951980","market":"nz","top_or_hot":-1,"title":"BRIEF-Cingulate Presents Positive Phase 3 Results for CTx-1301","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Cingulate Presents Positive Phase 3 Results for CTx-1301</title></head><body><p><span>Oct 28 (Reuters)</span><span> - </span>Cingulate Inc <span>CING.O</span>:</p><ul><li><p>CINGULATE PRESENTS POSITIVE PHASE 3 RESULTS FOR CTX-1301 DEMONSTRATING STATISTICALLY SIGNIFICANT EFFICACY AND ENTIRE ACTIVE-DAY SYMPTOM CONTROL</p></li></ul><p>Source text: <span>ID:nGNX57NmLC</span></p><p>Further company coverage: <span>CING.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Cingulate Presents Positive Phase 3 Results for CTx-1301</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Cingulate Presents Positive Phase 3 Results for CTx-1301\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-28 20:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Cingulate Presents Positive Phase 3 Results for CTx-1301</title></head><body><p><span>Oct 28 (Reuters)</span><span> - </span>Cingulate Inc <span>CING.O</span>:</p><ul><li><p>CINGULATE PRESENTS POSITIVE PHASE 3 RESULTS FOR CTX-1301 DEMONSTRATING STATISTICALLY SIGNIFICANT EFFICACY AND ENTIRE ACTIVE-DAY SYMPTOM CONTROL</p></li></ul><p>Source text: <span>ID:nGNX57NmLC</span></p><p>Further company coverage: <span>CING.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251028:nTUABXQ6SB:1","article_id":"2578951980","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2578951980","pubTimestamp":1761654141,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Cingulate Presents Positive Phase 3 Results for CTx-1301Oct 28 (Reuters) - Cingulate Inc CING.O:CINGULATE PRESENTS POSITIVE PHASE 3 RESULTS FOR CTX-1301 DEMONSTRATING STATISTICALLY SIGNIFICANT E","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","CINGW":"CINGULATE INC C/WTS 03/12/2026 (TO PUR COM)","CING":"CINGULATE INC."},"translate_title":"BRIEF-Cingulate提供CTx-1301的积极3期结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CING":0.9,"CINGW":0.9},"content_text":"BRIEF-Cingulate Presents Positive Phase 3 Results for CTx-1301Oct 28 (Reuters) - Cingulate Inc CING.O:CINGULATE PRESENTS POSITIVE PHASE 3 RESULTS FOR CTX-1301 DEMONSTRATING STATISTICALLY SIGNIFICANT EFFICACY AND ENTIRE ACTIVE-DAY SYMPTOM CONTROLSource text: ID:nGNX57NmLCFurther company coverage: CING.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2578951980","isCrawlerRequest":true}